Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends
New

OMER
Omeros Corporation
stock NASDAQ

At Close
6/24/2022 3:59:56 PM EDT
2.62USD-0.945%(-0.03)6,787,924
2.61Bid   2.63Ask   0.02Spread IEX
Pre-market
1969-12-31
0.00USD-100.000%(-2.65)0
After-hours
1969-12-31
0.00USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
164.353M
CEO
Gregory Demopulos
Headquarters
Seattle, Washington, USA
Industry
Biotechnology
Next Earnings
2022-08-08 (43d)
Related
AKRXDRRXBTXJNJPFEGENEXLV
Jan 21, 2022
03:55PM EST  Omeros Option Alert: Feb 18 $7 Calls Sweep (45) near the Ask: 832 @ $0.4 vs 314 OI; Earnings 2/28 After Close [est] Ref=$5.295   Benzinga
Jan 20, 2022
08:28AM EST  The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug   Benzinga
Jan 19, 2022
10:26PM EST  Omeros Corp. (OMER) confirmed Wednesday that earlier this month the company submitted to the U.S. Food and Drug Administration its response to the Agency's complete Response Letter or CRL for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy or HSCT-TMA.   RTTNews
05:56PM EST  Omeros Confirms Submission Of Response To FDA Regarding BLA For Narsoplimab In Treatment Of HSCT-TMA   Benzinga
05:52PM EST  Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA   Business Wire
More News
Stats
Avg. Vol. 10 Day
1,643,083
Avg. Vol. 30 Day
1,367,035
Employees
213
Market Cap
164,352,639
Shares Out.
62,730,015
Float
60,136,537
P/E Ratio
-1.50
EPS (ttm)
-1.990
On/Off Exchange
69%/31%
6 Month Beta
1.76
1 Year Beta
1.51
2 Year Beta
1.31
3 Year Beta
1.06
52 Week Low
1.86
52 Week High
16.57
SMA50
2.55
SMA200
5.24
1 Week
+31.00%
1 Month
+1.55%
3 Month
-57.74%
6 Month
-64.01%
1 Year
-83.22%
2 Year
-82.74%
5 Year
-89.43%
Profile
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.

OMER Stock Summary

Omeros Corporation (NASDAQ:OMER) stock price today is $2.62, and today's volume is 6,787,924. OMER is down -0.945% today. The 30 day average volume is 1,367,035. OMER market cap is 164.353M with 62,730,015 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter @chartexchange_
© 2020 - 2022 ChartExchange LLC